Holen Sie sich die Stockscreener-App
125.27
1.08%
-1.37
Handel nachbörslich:
125.05
-0.22
-0.18%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$126.64
Offen:
$126.96
24-Stunden-Volumen:
9.35M
Relative Volume:
1.32
Marktkapitalisierung:
$155.42B
Einnahmen:
$29.05B
Nettoeinkommen (Verlust:
$8.11B
KGV:
19.40
EPS:
6.4563
Netto-Cashflow:
$9.16B
1W Leistung:
+0.95%
1M Leistung:
+3.58%
6M Leistung:
+16.67%
1J Leistung:
+38.90%
1-Tages-Spanne:
$124.49
$128.25
1-Wochen-Bereich:
$123.32
$128.70
52-Wochen-Spanne:
$88.57
$128.70
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
125.27 | 157.12B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,070.16 | 948.45B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.05 | 491.26B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.51 | 417.60B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
126.54 | 244.28B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.40 | 242.64B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
GILD: Truist Securities Lowers Price Target for Gilead Sciences - GuruFocus
From the Lab to Runway: HIV Unwrapped Helps Transform Stigma by Giving Lab Coats a Makeover - Gilead Sciences
BioStock: Sprint Bioscience sells cancer program TREX1 to Gilead - TradingView
Prudential Financial Inc. Buys 486,379 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Foundation Commits Over $3 Million to Address Food Insecurity - Yahoo Finance
Gilead Sciences, Inc. $GILD Shares Bought by Nemes Rush Group LLC - MarketBeat
Truist Securities assumes coverage on Gilead Sciences stock with Buy rating - Investing.com
Magnetar Financial LLC Purchases New Shares in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by MAI Capital Management - MarketBeat
Centric Wealth Management Purchases 2,736 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Charles Schwab Investment Management Inc. Lowers Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Sprint Bioscience Surges After Selling Cancer Program to Gilead Sciences - MarketScreener
Healthcare companies expand their 'suitcases' - ecns.cn
Sprint Bioscience sells the TREX1 program to Gilead - TradingView
Is Ameya Precision Engineers Limited a Safe Haven Stock During Market StressTrade Execution Strategies & See Risk Factors Before Making Any Move - earlytimes.in
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
TD Waterhouse Canada Inc. Sells 120,736 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by Rhumbline Advisers - MarketBeat
Mufg Securities Americas Inc. Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Journey Strategic Wealth LLC Buys 4,053 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
DNB Asset Management AS Purchases 61,277 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
American Century Companies Inc. Boosts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Legal & General Group Plc Sells 487,170 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Mediolanum International Funds Ltd Purchases 82,402 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Swiss National Bank Grows Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Handelsbanken Fonder AB Buys 69,440 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Rockefeller Capital Management L.P. Decreases Position in Gilead Sciences, Inc. $GILD - MarketBeat
CFC Planning Co LLC Buys New Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Brandywine Global Investment Management LLC Sells 5,650 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
First Deliveries of Gilead's Twice-Yearly HIV Prevention Therapy in Sub-Saharah Africaand What it Means for Ending the HIV Epidemic - Gilead Sciences
First Deliveries of Gilead's Twice-Yearly HIV Prevention Therapy in Sub-Saharan Africa – and What it Means for Ending the HIV Epidemic - Gilead Sciences
Bob Allen joins Gilead’s public affairs team - PRWeek
Gilead (GILD) Unit Receives FDA Orphan Drug Designation - GuruFocus
Gilead Sciences (GILD) Receives Upgrade Amid HIV Division Streng - GuruFocus
Mizuho Adjusts Price Target on Gilead Sciences to $140 From $131, Maintains Outperform Rating - MarketScreener
Prudential PLC Sells 27,809 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead abruptly parts ways with general counsel—Chutes & Ladders - Fierce Biotech
Mizuho raises Gilead Sciences stock price target to $140 on HIV outlook - Investing.com
Ensign Peak Advisors Inc Buys 152,685 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
How Gilead’s Lenacapavir Launch and New HIV Data May Shape GILD’s Global Outlook - simplywall.st
Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength (GILD) - Seeking Alpha
South Africa is urged by advocates to issue a compulsory license for Gilead's HIV prevention drug - statnews.com
Gilead’s Top Lawyer Leaving After Big Stock Sale, Settlements - Bloomberg Law News
Gilead Sciences (NASDAQ:GILD) Reaches New 1-Year HighHere's What Happened - MarketBeat
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock - Yahoo Finance
Connor Clark & Lunn Investment Management Ltd. Has $673,000 Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock enhance shareholder value2025 Support & Resistance & Advanced Technical Signal Analysis - newser.com
Will Gilead Sciences Inc. (GIS) stock outperform energy sector in 2025Weekly Market Report & Verified Stock Trade Ideas - newser.com
Gilead Sciences (GILD): Taking Stock of Valuation as Shares Approach Analyst Targets - Yahoo Finance
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock outperform Dow JonesQuarterly Trade Summary & Precise Swing Trade Alerts - newser.com
Identifying reversal signals in Gilead Sciences Inc.July 2025 Highlights & Expert Approved Momentum Ideas - newser.com
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.58%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):